



## **Catabasis Pharmaceuticals to Host Investor Day in New York City on November 17**

*-- Presentations Will Include Edasalonexent and Rare Disease Pipeline --*

**CAMBRIDGE, MA, November 3, 2016** – [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will be hosting its first Investor Day and simultaneous webcast on November 17, 2016 from 8:30am to 11:30am ET in New York City. The Company will discuss corporate strategy and its pipeline in rare diseases, including presentations on edasalonexent (CAT-1004) and Duchenne muscular dystrophy (DMD) by external Duchenne experts and Catabasis leadership team members.

Presenting at the event:

Key opinion leaders:

- Craig M. McDonald, M.D., *UC Davis NeuroNEXT Program Director*, University of California
- H. Lee Sweeney, Ph.D., *UF Myology Institute Director*, University of Florida

Catabasis leadership team:

- Joanne M. Donovan, M.D., Ph.D., *Chief Medical Officer and Senior Vice President, Clinical Development*
- Jill C. Milne, Ph.D., *Co-Founder and Chief Executive Officer*
- Rick Modi, *Chief Business Officer*
- Andrew Nichols, Ph.D., *Chief Scientific Officer*

The Investor Day is open to members of the professional investment community. To register, please email [CATB@macbiocom.com](mailto:CATB@macbiocom.com).

### **Webcast Information:**

Interested parties may access the live webcast of the event at <http://edge.media-server.com/m/p/7h9t7i6s> or via the investor section of the Catabasis website, [www.catabasis.com](http://www.catabasis.com). Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The webcast will be archived for 90 days.

### **About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

###

Corporate and Media Contact  
Andrea Matthews  
Catabasis Pharmaceuticals, Inc.  
T: (617) 349-1971  
[amatthews@catabasis.com](mailto:amatthews@catabasis.com)